Background: Although, a number of formulations have been developed for the treatment
of IBD yet the developed formulations are having side effects such as high dose, lack of
solubility and permeability problems at the site of action. Very few formulations have been developed
for the IBD treatment in the form of nanoparticles. Nanoparticles have shown their potential
in the recent findings in the treatment of IBD at cellular level. This research work aims to develop
nanosuspension of newly introduced drug Rifaximin currently available in the form of tablet for
the treatment of IBD. Rifaximin in the form of tablet is given in high dose concentration so to
avoid the large dose and to increase the permeability action of drug a nanosuspension is prepared
using a well known polymer Eudragit S 100 which is itself a colon targeted polymer and simultaneously
improves the site specific delivery of the drug.
Method: We thoroughly reviewed and tested the previous work for the development of nanoparticles
in the laboratory for the treatment of IBD. A number of research as well as review articles
were followed in order to get quality information. For this all the research as well as review work
was collected from the quality journals. A simple yet a high result oriented technique nanoprecipitation
was used for the development of nanoparticles.
Results: A total of 21 research and review papers were studied deeply. Before developing the final
formula a number of trials were carried out and from the trials, the formulation which showed better
release profile and presence of nanoparticles was then optimized and a total of five formulations
were developed. In each of the five formulations the concentration of the polymer and external
phase was varied along with the concentration change in P.F. 68 for getting a superior formulation
in terms of release, size and entrapment. The least size nanosuspension was subjected to
Transmission Electron Microscopy for confirmation of nanoparticles and to check the morphological
characters of the prepared nanoparticles and size of the nanoparticles was in the range of
19nm to 25nm. The prepared formulation was subjected to stability studies and it was freeze dried.
Conclusion: The outcome of this research work confirms the formation of nanoparticles and release
profile of the prepared nanosuspension proved its site specificity. The release graphs indicated
the release of the drug in colon proving its potential in the treatment of IBD and entrapment
study indicates the drug entrapment capacity for delivering the required concentration of drug at
the site of action. Moreover, the nanoformulation reduces the dose and the side effects due to its
specific targeting at the site of inflammation which makes it a better choice over the tablets.